Autopsy report · NCT03037645

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

“Phase 1b portion completed. Sponsor decided not to proceed with P2 portion of study. Vecabrutinib was very well tolerated, there was insufficient evidence of activity at the doses tested in the Phase 1b to advance to Phase 2.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 3 years 4 months before it stopped.
• 39 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Sunesis Pharmaceuticals

Sponsor type

Industry

Conditions

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoplasmacytoid Lymphoma; Mantle-Cell Lymphoma; Waldenstrom Macroglobulinemia; Diffuse Large B Cell Lymphoma

Interventions

SNS-062

Participants

39

Sites

11

Countries

United States

Trials that died the same way

• Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
  “Study was terminated by sponsor after Phase 1b as pre-defined signals of efficacy were not met in the Phase 1b dose expansion cohort.” (67% match in meaning)
• A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
  “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.” (66% match in meaning)
• Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2
  “business reasons-Phase 2/Part B not conducted. Study terminated after last patient enrolled in Phase 1/Part A” (66% match in meaning)
• Reparixin in COVID-19 Pneumonia - Efficacy and Safety
  “The sponsor has decided to start with a separate protocol for phase 3 and therefore this study was terminated with only phase 2.” (65% match in meaning)
• Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism
  “Lack of efficacy to proceed to Phase 2” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.